New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - haemophilus influenzae type b prp 5ug (conjugated with 12.5 mcg tetanus toxoid);  ; neisseria meningitidis group c polysaccharide 5ug (5 mcg men c polysaccharide conjugated to 5 mcg tetanus toxoid) - injection with diluent - 0.5 ml - active: haemophilus influenzae type b prp 5ug (conjugated with 12.5 mcg tetanus toxoid)   neisseria meningitidis group c polysaccharide 5ug (5 mcg men c polysaccharide conjugated to 5 mcg tetanus toxoid) excipient: sodium chloride sucrose tetanus toxoid trometamol hydrochloride sodium chloride water for injection - menitorix is indicated for the prevention of invasive diseases caused by haemophilus influenzae type b (hib) and neisseria meningitidis serogroup c (menc).

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - diphtheria toxoid, adsorbed 30 [iu] (not less than); hepatitis b surface antigen, recombinant 10ug; pertactin 8ug;  ; pertussis filamentous haemagglutinin 25ug;  ; pertussis toxoid, adsorbed 25ug;  ; polio virus type 1 40 dagu (/dose);  ; polio virus type 2 8 dagu (/dose);  ; polio virus type 3 32 dagu (/dose);  ; tetanus toxoid, adsorbed 40 [iu] (not less than); haemophilus influenzae vaccine, tetanus toxoid conjugate 10ug (covalently bonded to tetanus toxoid 20 - 40micrograms);   - suspension for injection - 0.5 ml - active: diphtheria toxoid, adsorbed 30 [iu] (not less than) hepatitis b surface antigen, recombinant 10ug pertactin 8ug   pertussis filamentous haemagglutinin 25ug   pertussis toxoid, adsorbed 25ug   polio virus type 1 40 dagu (/dose)   polio virus type 2 8 dagu (/dose)   polio virus type 3 32 dagu (/dose)   tetanus toxoid, adsorbed 40 [iu] (not less than) excipient: aluminium medium 199 sodium chloride water for injection active: haemophilus influenzae vaccine, tetanus toxoid conjugate 10ug (covalently bonded to tetanus toxoid 20 - 40micrograms)   excipient: aluminium as aluminium phosphate lactose - infanrix hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and haemophilus influenzae type b.

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - conjugate of haemophilus influenzae type b capsular polysaccharide (polyribosylribitol phosphate) and tetanus; conjugate of neisseria meningitides c capsular polysaccharide and tetanus toxoid (mean tt/ps ratio :1) - powder and solvent for solution for injection - 0.5 millilitre(s) - hemophilus influenzae b, combinations with meningococcus c, conjugated

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - diphtheria toxoid, adsorbed 30 lf u equivalent to not less than 20 iu; haemophilus influenzae type b polysaccharide 12ug ((polyribosylribitol phosphate) conjugated to tetanus protein (22-36 mcg)); hepatitis b virus surface antigen 10ug; pertussis filamentous haemagglutinin 25ug (adsorbed); pertussis toxoid, adsorbed 25ug; polio virus type 1 40 dagu (mahoney); polio virus type 2 8 dagu (mef-1); polio virus type 3 32 dagu (saukett); tetanus toxoid, adsorbed 10 lf u equivalent to not less than 40 iu - suspension for injection - active: diphtheria toxoid, adsorbed 30 lf u equivalent to not less than 20 iu haemophilus influenzae type b polysaccharide 12ug ((polyribosylribitol phosphate) conjugated to tetanus protein (22-36 mcg)) hepatitis b virus surface antigen 10ug pertussis filamentous haemagglutinin 25ug (adsorbed) pertussis toxoid, adsorbed 25ug polio virus type 1 40 dagu (mahoney) polio virus type 2 8 dagu (mef-1) polio virus type 3 32 dagu (saukett) tetanus toxoid, adsorbed 10 lf u equivalent to not less than 40 iu excipient: aluminium hydroxide amino acids dibasic sodium phosphate monobasic potassium phosphate sucrose trometamol water for injection - hexaxim is indicated for vaccination of infants from six weeks of age against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and invasive infections caused by haemophilus influenzae type b. use of this vaccine should be in accordance with the national recommendation as per the current immunisation handbook.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tetanus toxoid, quantity: 20 microgram/ml; meningococcal polysaccharide group c, quantity: 20 microgram/ml - injection, suspension - excipient ingredients: sodium chloride; water for injections; aluminium hydroxide hydrate - neisvac-c vaccine is indicated for active immunisation of children from 8 weeks of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis serogroup c.

Israel - English - Ministry of Health

sanofi israel ltd - conjugated to tetanus protein; diphtheria toxoid; filamentous haemagglutinin (fha); haemophilus influenzae type b polysaccharide; pertussis toxoid (pt); polio type i (mohoney); polio type ii ( m.e.f.1); polio type iii (saukett); tetanus toxoid - powder and suspension for suspension for injection - polio type iii (saukett) 32 du / 0.5 ml; polio type ii ( m.e.f.1) 8 du / 0.5 ml; polio type i (mohoney) 40 du / 0.5 ml; filamentous haemagglutinin (fha) 25 mcg / 0.5 ml; pertussis toxoid (pt) 25 mcg / 0.5 ml; tetanus toxoid 40 iu / 0.5 ml; diphtheria toxoid 30 iu / 0.5 ml; haemophilus influenzae type b polysaccharide 10 mcg / 0.5 ml; conjugated to tetanus protein 18-30 mcg / 0.5 ml - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus - active immunisation against diphtheria, tetanus, pertussis, poliomyelitis and invasive infections caused by haemophilus influenzae type b (meningitis, septicaemia, cellulitis, arthritis, epiglottitis, …)• for primary vaccination in infants.• for booster in children who have previously received a primary vaccination with this vaccine or a diphtheria-tetanus-whole-cell or acellular pertussis poliomyelitis vaccine, whether mixed or not with freeze-dried conjugate haemophilus influenzae type b vaccine.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - haemophilus influenza type b polyribose ribitol phosphate,meningococcal polysaccharide group c,tetanus toxoid -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi pasteur msd ltd - human poliovirus type 3 inactivated; tetanus toxoid; pertussis antigens; human poliovirus type 1 inactivated; human poliovirus type 2 inactivated; diphtheria toxoid; haemophilus influenzae type b polysaccharide protein conjugate - suspension for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - haemophilus influenzae vaccine, tetanus toxoid conjugate 10ug (20-40mcg of tetanus toxoid per dose);   - powder for injection with diluent - 0.5 ml - excipient: sodium chloride water for injection active: haemophilus influenzae vaccine, tetanus toxoid conjugate 10ug (20-40mcg of tetanus toxoid per dose)   excipient: lactose water for injection - hiberix is indicated for active immunisation of all infants from the age of 6 weeks against disease caused by hib. hiberix does not protect against diseases due to other types of h. influenzae, nor against meningitis caused by other organisms.

Ireland - English - HPRA (Health Products Regulatory Authority)

gsk vaccines s.r.l. - meningococcal group c oligosaccharide; corynebacterium diphtheriae crm197 protein - suspension for injection in pre-filled syringe - 10 - meningococcal vaccines; other meningococcal polyvalent purified polysaccharides antigen - meningococcal vaccines - active immunisation of children from 2 months of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis group c.